A Double-Blind, Placebo-Controlled Trial Assessing Pramlintide Treatment in the Setting of Intensive Insulin Therapy in Type 1 Diabetes
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—To assess safety, efficacy, and tolerability of pramlintide dose escalation with proactive mealtime insulin reduction, followed by insulin optimization, in patients with type 1 diabetes. RESEARCH DESIGN AND METHODS—This 29-week, double-blind, placebo-controlled study randomized 296 patients to pramlintide or placebo as an adjunct to insulin. During initiation, pramlintide was escalated from 15 to 60 μg/meal (15-μg increments) with recommended reductions (30–50%) in mealtime insulin. Insulin was subsequently adjusted to optimize glycemic control. End points included safety and change in HbA1c (A1C), postprandial glucose, insulin, weight, and tolerability. RESULTS—Baseline A1C was 8.1% for both groups and at week 29 had decreased comparably (pramlintide −0.5% [95% CI −0.61 to −0.33]; placebo −0.5% [−0.63 to −0.35]). Pramlintide treatment significantly reduced postprandial glucose excursions (incremental area under the curve [AUC]0–3h: pramlintide −175 ± 40, placebo −64 ± 38 mg · h−1 · dl−1; P < 0.0005) and weight (pramlintide −1.3 ± 0.30, placebo +1.2 ± 0.30 kg; P < 0.0001). At week 29, insulin dose decreased by 28 and 4% in pramlintide- and placebo-treated groups, respectively. Nausea, reported by 63 and 36% of patients in pramlintide and placebo groups (P < 0.01), respectively, was predominately mild to moderate in intensity. Severe hypoglycemia rates were low in both groups (pramlintide 0.57 ± 0.09, placebo 0.30 ± 0.06 event rate/patient-year; P < 0.05), with increased rates observed in patients remaining at 30 μg pramlintide. CONCLUSIONS—Pramlintide dose escalation with reduced mealtime insulin was effective during therapy initiation in patients with type 1 diabetes. While both groups experienced equivalent A1C reductions relative to placebo, pramlintide-treated patients experienced reductions in postprandial glucose excursions and weight, not achievable with insulin therapy alone.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ultrarapid insulins (ie, faster aspart, lispro aabc) have demonstrated earlier time of onset and action but similar duration of action.1165”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1165]
Citations
Cites
Monnier, L., Lapinski, H., & Colette, C. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.881 · Cited by 1,461
Ceriello, A., & Motz, E. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000122852.22604.78 · Cited by 1,378
Hanefeld, M., Fischer, S., Julius, U., Schulze, J., Schwanebeck, U., Schmechel, H., Ziegelasch, H. J., & Lindner, J. (1996) · Diabetologia · doi:10.1007/s001250050617 · Cited by 873
Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial
(1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90605-w · Cited by 807
Epidemiology of severe hypoglycemia in the diabetes control and complications trial
(1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)80085-z · Cited by 807
de Vegt, F., Dekker, J. M., Ruhé, H. G., Stehouwer, C. D. A., Nijpels, G., Bouter, L. M., & Heine, R. J. (1999) · Diabetologia · doi:10.1007/s001250051249 · Cited by 613
Balkau, B., Shipley, M., Jarrett, R. J., Pyörälä, K., Pyörälä, M., Forhan, A., & Eschwège, E. (1998) · Diabetes Care · doi:10.2337/diacare.21.3.360 · Cited by 598
Purnell, J. Q., Hokanson, J. E., Marcovina, S. M., Steffes, M. W., Cleary, P. A., & Brunzell, J. D. (1998) · JAMA · doi:10.1001/jama.280.2.140 · Cited by 469
Should minimal blood glucose variability become the gold standard of glycemic control?
Hirsch, I. B., & Brownlee, M. (2005) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2004.10.001 · Cited by 405
Weight Gain Associated With Intensive Therapy in the Diabetes Control and Complications Trial
The DCCT Research Group (1988) · Diabetes Care · doi:10.2337/diacare.11.7.567 · Cited by 345
Cited by
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s009 · Cited by 972
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s009 · Cited by 914
Differentiation of diabetes by pathophysiology, natural history, and prognosis
Skyler, J. S., Bakris, G. L., Bonifacio, E., Darsow, T., Eckel, R. H., Groop, L., Groop, P.-H., Handelsman, Y., Insel, R. A., Mathieu, C., et al. (2017) · Diabetes · doi:10.2337/db16-0806 · Cited by 823
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s009 · Cited by 739
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Handelsman, Y., Mechanick, J. I., Blonde, L., Grunberger, G., Bloomgarden, Z. T., Bray, G. A., Dagogo-Jack, S., Davidson, J. A., Einhorn, D., Ganda, O., et al. (2011) · Endocrine Practice · doi:10.4158/ep.17.s2.1 · Cited by 513
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms
Corbin, K. D., Driscoll, K. A., Pratley, R. E., Smith, S. R., Maahs, D. M., Mayer-Davis, E. J., & Advancing Care for Type 1 Diabetes and Obesity Network (ACT1ON) (2018) · Endocrine Reviews · doi:10.1210/er.2017-00191 · Cited by 262
Ahrén, B., Hirsch, I. B., Pieber, T. R., Mathieu, C., Gómez-Peralta, F., Hansen, T. K., Philotheou, A., Birch, S., Christiansen, E., Jensen, T. J., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0690 · Cited by 262
New frontiers in the treatment of type 1 diabetes
Warshauer, J. T., Bluestone, J. A., & Anderson, M. S. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.11.017 · Cited by 259
Pharmacotherapy of type 2 diabetes: An update
Upadhyay, J., Polyzos, S. A., Perakakis, N., Thakkar, B., Paschou, S. A., Katsiki, N., Underwood, P., Park, K.-H., Seufert, J., Kang, E. S., et al. (2018) · Metabolism · doi:10.1016/j.metabol.2017.08.010 · Cited by 187
Haidar, A., Tsoukas, M. A., Bernier-Twardy, S., Yale, J.-F., Rutkowski, J., Bossy, A., Pytka, E., El Fathi, A., Strauss, N., & Legault, L. (2020) · Diabetes Care · doi:10.2337/dc19-1922 · Cited by 138
Weinzimer, S. A., Sherr, J. L., Cengiz, E., Kim, G., Ruiz, J. L., Carria, L., Voskanyan, G., Roy, A., & Tamborlane, W. V. (2012) · Diabetes Care · doi:10.2337/dc12-0330 · Cited by 134
Kowalski, A. J. (2009) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0031 · Cited by 127
Gingras, V., Taleb, N., Roy‐Fleming, A., Legault, L., & Rabasa‐Lhoret, R. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13052 · Cited by 113
Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus
Frandsen, C. S., Dejgaard, T. F., & Madsbad, S. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00039-5 · Cited by 101
Pramlintide and the treatment of diabetes: a review of the data since its introduction
Younk, L. M., Mikeladze, M., & Davis, S. N. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.581663 · Cited by 100
Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes
Ryan, G., Jobe, L., & Briscoe, T. (2008) · Drug Design, Development and Therapy · doi:10.2147/dddt.s3225 · Cited by 98
Role of Amylin in Type 1 and Type 2 Diabetes
Hieronymus, L., & Griffin, S. (2015) · The Diabetes Educator · doi:10.1177/0145721715607642 · Cited by 86
Insulin Resistance in Type 1 Diabetes: Pathophysiological, Clinical, and Therapeutic Relevance
Apostolopoulou, M., Lambadiari, V., Roden, M., & Dimitriadis, G. D. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnae032 · Cited by 90
Moon, J. S., Kang, S., Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Seo, J. A., Kim, M. K., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0249 · Cited by 90
Obesity in Patients with Type 1 Diabetes: Links, Risks and Management Challenges
Vilarrasa, N., San Jose, P., Rubio, M. Á., & Lecube, A. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s223618 · Cited by 88
Hoogwerf, B. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s1978 · Cited by 87
Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus
Singh‐Franco, D., Robles, G. I., & Gazze, D. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.04.005 · Cited by 84
Kang, S., Kang, S. M., Choi, J. H., Ko, S., Koo, B. K., Kwon, H.-S., Kim, M. K., Kim, S. Y., Kim, S., Kim, Y., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0469 · Cited by 84
SGLT inhibitor adjunct therapy in type 1 diabetes
McCrimmon, R. J., & Henry, R. R. (2018) · Diabetologia · doi:10.1007/s00125-018-4671-6 · Cited by 77
Liraglutide as Additional Treatment to Insulin in Obese Patients with Type 1 Diabetes Mellitus
Kuhadiya, N. D., Malik, R., Bellini, N. J., Patterson, J. L., Traina, A. N., Makdissi, A., & Dandona, P. (2013) · Endocrine Practice · doi:10.4158/ep13065.or · Cited by 81
Neuroendocrine hormone amylin in diabetes
Zhang, X., Pan, Y.-H., Huang, Y., & Zhao, H. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i9.189 · Cited by 80
Pramlintide in the Treatment of Diabetes Mellitus
Edelman, S. V., Maier, H., & Wilhelm, K. (2008) · BioDrugs · doi:10.2165/0063030-200822060-00004 · Cited by 75
Self-citationPramlintide in the management of insulin-using patients with type 2 and type 1 diabetes
Pullman, J. R., Darsow, T., & Frías, J. P. (2006) · Vascular Health and Risk Management · doi:10.2147/vhrm.2006.2.3.203 · Cited by 69
Importance of Postprandial Glucose in Relation to A1C and Cardiovascular Disease
Hershon, K. S., Hirsch, B. R., & Odugbesan, O. (2019) · Clinical Diabetes · doi:10.2337/cd18-0040 · Cited by 67
Maikawa, C. L., Autzen, A. A. A., Zou, L., Roth, G. A., Gale, E. C., Stapleton, L. M., Baker, S. W., Mann, J. L., Yu, A. C., Correa, S., et al. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-0555-4 · Cited by 66
Efficacy and Safety of Tirzepatide in Overweight and Obese Adult Patients with Type 1 Diabetes
Garg, S. K., Akturk, H. K., Kaur, G., Beatson, C., & Snell-Bergeon, J. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0050 · Cited by 65
Self-citationThe Alpha-Cell as Target for Type 2 Diabetes Therapy
Christensen, M., Bagger, J. I., Vilsboll, T., & Knop, F. K. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.369 · Cited by 65
Obesity treatment: novel peripheral targets
Field, B. C. T., Chaudhri, O. B., & Bloom, S. R. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03522.x · Cited by 64
Sonne, N., Karsdal, M. A., & Henriksen, K. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101109 · Cited by 63
Adjunct therapy for type 1 diabetes mellitus
Lebovitz, H. E. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.49 · Cited by 59
IAPP and type 1 diabetes: implications for immunity, metabolism and islet transplants
Denroche, H. C., & Verchere, C. B. (2018) · Journal of Molecular Endocrinology · doi:10.1530/jme-17-0138 · Cited by 58
How Does Treatment Satisfaction Work?
Peyrot, M., & Rubin, R. R. (2009) · Diabetes Care · doi:10.2337/dc08-2256 · Cited by 56
Bode, B. W., & Garg, S. K. (2015) · Endocrine Practice · doi:10.4158/ep15869.ra · Cited by 56
Self-citationQiao, Y.-C., Ling, W., Pan, Y.-H., Chen, Y.-L., Zhou, D., Huang, Y.-M., Zhang, X.-X., & Zhao, H.-L. (2017) · Oncotarget · doi:10.18632/oncotarget.16008 · Cited by 54
Pettus, J., Boeder, S. C., Christiansen, M. P., Denham, D. S., Bailey, T. S., Akturk, H. K., Klaff, L. J., Rosenstock, J., Cheng, M. H. M., Bode, B. W., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02011-x · Cited by 54
Self-citationPotential role of non‐insulin adjunct therapy in Type 1 diabetes
George, P., & McCrimmon, R. J. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03744.x · Cited by 51
Gut Peptide Hormones and Pediatric Type 1 Diabetes Mellitus
Huml, M., Kobr, J., Siala, K., Varvařovská, J., Pomahačová, R., Karlíková, M., & Sýkora, J. (2011) · Physiological Research · doi:10.33549/physiolres.931995 · Cited by 51
The Role of Pramlintide for Weight Loss
Dunican, K. C., Adams, N. M., & Desilets, A. R. (2010) · Annals of Pharmacotherapy · doi:10.1345/aph.1m210 · Cited by 50
Marrero, D. G., Crean, J., Zhang, B., Kellmeyer, T., Gloster, M., Herrmann, K., Rubin, R., Fineberg, N., & Kolterman, O. (2007) · Diabetes Care · doi:10.2337/dc06-1026 · Cited by 49
Self-citationAmylin, Another Important Neuroendocrine Hormone for the Treatment of Diabesity
Eržen, S., Tonin, G., Jurišić‐Eržen, D., & Klen, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031517 · Cited by 49
Insulin resistance, role of metformin and other non-insulin therapies in pediatric type 1 diabetes
Bacha, F. F., & Bartz, S. K. (2015) · Pediatric Diabetes · doi:10.1111/pedi.12337 · Cited by 46
Riddle, M. C., Nahra, R., Han, J., Castle, J. R., Hanavan, K., Hompesch, M., Huffman, D. M., Strange, P., & Öhman, P. (2018) · Diabetes Care · doi:10.2337/dc18-1091 · Cited by 46
Reducing Type 1 Diabetes Mortality: Role for Adjunctive Therapies?
Snaith, J. R., Holmes-Walker, D. J., & Greenfield, J. R. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2019.11.007 · Cited by 45
BOEDER, S. C., & Edelman, S. V. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13749 · Cited by 44
Self-citationNovel strategy for the use of leptin for obesity therapy
Tam, C. S., Lecoultre, V., & Ravussin, E. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.619974 · Cited by 43
Chase, H. P., Lutz, K., Pencek, R., Zhang, B., & Porter, L. (2009) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2009.03.012 · Cited by 43
Self-citationEfficacy and harms of the hypoglycemic agent pramlintide in diabetes mellitus
Lee, N. J., Norris, S. L., & Thakurta, S. (2010) · The Annals of Family Medicine · doi:10.1370/afm.1174 · Cited by 39
Gut Hormones as Potential New Targets for Appetite Regulation and the Treatment of Obesity
Field, B. C. T., Wren, A., Cooke, D., & Bloom, S. R. (2008) · Drugs · doi:10.2165/00003495-200868020-00002 · Cited by 38
Karl, D. M., Philis‐Tsimikas, A., Darsow, T., Lorenzi, G. M., Kellmeyer, T., Lutz, K., Wang, Y., & Frías, J. P. (2007) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2006.0013 · Cited by 38
Self-citationAdjunctive therapy for glucose control in patients with type 1 diabetes
Harris, K., Boland, C. L., Meade, L. T., & Battise, D. M. (2018) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s141700 · Cited by 37
Garg, S. V., Kaur, G., Renner, D. C., Lanning, M. S., Mason, E., Beatson, C. R., Ciesco, K., & Snell‐Bergeon, J. K. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0481 · Cited by 33
Self-citationRiddle, M. C., Yuen, K. C. J., de Bruin, T. W. A., Herrmann, K., Xu, J. L., Öhman, P., & Kolterman, O. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12504 · Cited by 31
Self-citationAlpha cell function in type 1 diabetes
Hughes, D. S., & Narendran, P. (2014) · The British Journal of Diabetes · doi:10.15277/bjdvd.2014.014 · Cited by 30
Wright, L. A.-C., & Hirsch, I. B. (2019) · Diabetic Medicine · doi:10.1111/dme.13941 · Cited by 29
Andersen, G., Meiffren, G., Famulla, S., Heise, T., Ranson, A., Seroussi, C., Eloy, R., Gaudier, M., Charvet, R., Chan, Y., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14302 · Cited by 29
Peyrot, M., Rubin, R. R., Polonsky, W. H., & Jennie Best, H. (2010) · Current Medical Research and Opinion · doi:10.1185/03007991003634759 · Cited by 27
Metabolic Control in Type 1 Diabetes: Is Adjunctive Therapy the Way Forward?
Warnes, H., Helliwell, R., Pearson, S. M., & Ajjan, R. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0496-z · Cited by 27
Neuroprotective Effects of Amylin Analogues on Alzheimer’s Disease Pathogenesis and Cognition
Grizzanti, J., Corrigan, R. R., & Casadesús, G. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180433 · Cited by 26
Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes
Galderisi, A., Sherr, J., VanName, M., Carria, L., Zgorski, M., Tichy, E., Weyman, K., Cengiz, E., Weinzimer, S., & Tamborlane, W. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02265 · Cited by 25
Herrmann, K., Frias, J. P., Edelman, S. V., Lutz, K., Shan, K., Chen, S., Maggs, D., & Kolterman, O. G. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.05.2635 · Cited by 25
Self-citationAdjuvantes no tratamento da hiperglicemia do diabetes melito tipo 1
Gabbay, M. A. L. (2008) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302008000200015 · Cited by 23
Micheletto, F., Man, C. D., Kolterman, O., Chiquette, E., Herrmann, K., Schirra, J. R. J., Kovatchev, B. P., & Cobelli, C. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0054 · Cited by 23
Self-citationPencek, R., Roddy, T., Peters, Y., Young, M. B. D., Herrmann, K., Meller, L., Nguyen, H. T., Chen, S., & Lutz, K. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01201.x · Cited by 23
Self-citationField, B. C. T. (2014) · British Medical Bulletin · doi:10.1093/bmb/ldu001 · Cited by 23
Herrmann, K., Brunell, S. C., Li, Y., Zhou, M., & Maggs, D. G. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0326-5 · Cited by 21
Self-citationNoninsulin pharmacological management of type 1 diabetes mellitus
Garg, V. (2011) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.83053 · Cited by 21
Herrmann, K., Zhou, M., Wang, A., & de Bruin, T. W. (2016) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-016-0030-z · Cited by 21
Rubin, R. R., & Peyrot, M. F. (2009) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721708326989 · Cited by 21
Optimizing diabetes treatment in the presence of obesity
Esquivel, M. A., & Lansang, M. C. (2017) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.84.s1.04 · Cited by 19
Huffman, D. M., McLean, G. W., & Seagrove-Guffey, M. (2009) · Endocrine Practice · doi:10.4158/ep09044.orr1 · Cited by 19
Peyrot, M., Rubin, R. R., & Polonsky, W. H. (2008) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2008.0031 · Cited by 18
Non-insulin pharmacological therapies for treating type 1 diabetes
Frandsen, C. S., Dejgaard, T. F., Madsbad, S., & Holst, J. J. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1483339 · Cited by 18
Adjunct therapies in treatment of type 1 diabetes
Goyal, I., Sattar, A., Johnson, M., & Dandona, P. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.13078 · Cited by 18
Approaches to Help People With Diabetes Overcome Barriers for Improved Health Outcomes
Siminerio, L. M. (2008) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721707313938 · Cited by 18
Recent developments in adjunct therapies for type 1 diabetes
Timmons, J. G., Littlejohn, L., Boyle, J. G., & Petrie, J. R. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2159806 · Cited by 17
Control of Postprandial Glucose Levels with Insulin in Type 2 Diabetes
Blevins, T. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.07.2313 · Cited by 17
Management of type 1 diabetes mellitus
Dennedy, M. C., & Dinneen, S. F. (2010) · Medicine · doi:10.1016/j.mpmed.2010.08.002 · Cited by 17
Pramlintide: Clinical Strategies for Success
Alrefai, H. A., Latif, K. A., Hieronymus, L. B., Weakley, C. R., & Moss, R. J. (2010) · Diabetes Spectrum · doi:10.2337/diaspect.23.2.124 · Cited by 16
The story of amylin: from physiology to therapy
Secher, A., Lutz, T. A., & Raun, K. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01465-4 · Cited by 16
Ultra‐Fast Insulin–Pramlintide Co‐Formulation for Improved Glucose Management in Diabetic Rats
Maikawa, C. L., Chen, P. C., Vuong, E. T., Nguyen, L. T., Mann, J. L., d’Aquino, A. I., Lal, R., Maahs, D. M., Buckingham, B. A., & Appel, E. A. (2021) · Advanced Science · doi:10.1002/advs.202101575 · Cited by 16
Pharmacological therapies to address obesity in type 1 diabetes
Casu, A., Bilal, A., & Pratley, R. E. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000555 · Cited by 16
From pumps to prevention: recent advances in the treatment of type 1 diabetes
Sherr, J. L., Cengiz, E., & Tamborlane, W. V. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.06.011 · Cited by 16
Rubin, R. R., & Peyrot, M. F. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x210804 · Cited by 16
Garg, S. K., Snell-Bergeon, J., Kaur, G., & Beatson, C. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0023 · Cited by 15
Self-citationAdjuvant Pharmacotherapies to Insulin for the Treatment of Type 1 Diabetes
Tosur, M., REDONDO, M. J., & Lyons, S. K. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1041-1 · Cited by 15
Managing obesity in adults with type 1 diabetes
Campos, A., Gutiérrez, R. D. J. R., Galindo, R. J., McCoy, R. G., & Andrade, M. D. H. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111983 · Cited by 14
Double Diabetes: A Growing Problem Requiring Solutions
Popovic, D. S., & Παπάνας, Ν. (2021) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1392-0590 · Cited by 14
Fang, J., Landersdorfer, C. B., Cirincione, B. B., & Jusko, W. J. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9409-7 · Cited by 14
Optimizing Diabetes Treatment Using an Amylin Analogue
Edelman, S. V. (2008) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721707313939 · Cited by 14
Self-citationLo, M. C., & Lansang, M. C. (2010) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3181ec9eb2 · Cited by 14
Tsushima, Y., Zhou, K., Bena, J., & Kashyap, S. R. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.01.008 · Cited by 13
The latest pharmacotherapy options for type 1 diabetes
Ludvigsson, J. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.855197 · Cited by 13
Metadata
- Authors
- Edelman, S., Garg, S., Frias, J., Maggs, D., Wang, Y., Zhang, B., Strobel, S., Lutz, K., & Kolterman, O.
- Affiliations
- Division of Diabetes/Metabolism, San Diego VA Medical Center, San Diego, California
- Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, Denver, Colorado
- Amylin Pharmaceuticals, San Diego, California
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2006-10-01
- Volume
- 29
- Issue
- 10
- Pages
- 2189-2195
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2126969411
- Cited by
- 166
- References
- 25
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 8 · 2023: 2 · 2022: 5 · 2021: 6 · 2020: 10 · 2019: 10 · 2018: 15 · 2017: 6 · 2016: 9 · 2015: 7 · 2014: 5 · 2013: 5 · 2012: 6
- FWCI
- 9.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- type 1 diabetes, intensive insulin therapy, glycemic control, HbA1c, postprandial blood glucose, weight loss, nausea, hypoglycemia, GLP-1 receptor agonists, dose escalation, weight gain, weight loss maintenance
- MeSH terms
- Adult, Amyloid, Blood Glucose, Body Weight, Diabetes Mellitus, Type 1, Double-Blind Method, Eating, Female, Glycated Hemoglobin, Humans, Insulin, Male, Middle Aged, Islet Amyloid Polypeptide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.